For Immediate ReleaseChicago, IL – October 29, 2024 – Today, Zacks Equity Research like Inspire Medical Systems (INSP) , 10x Genomics (TXG) and Omnicell, Inc. (OMCL) .Industry: Medical Info SystemsLink: https://www.zacks.com/commentary/2358816/3-medical-info-systems-stocks-to-gain-from-healthcare-digitizationStarting from healthcare resource management to efficient handling of medical records and patient data, the Medical Info Systems industry is rapidly expanding its boundaries with each passing day. Banki ...

Omnicell (OMCL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. Indiv ...

Here are two stocks with buy rank and strong momentum characteristics for investors to consider today, October 4: Omnicell, Inc. (OMCL) : This pharmaceutical technology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 16.7% over the last 60 days. Omnicell's shares gained 56.3% over the last three months compared with the S&P 500's advanced of 2.3%. The company possesses a Momentum Score of B. ServisFirst Bancshares, Inc. (SFBS) : This bank holdi ...

Omnicell (OMCL) is moving closer to achieving the industry-defined vision of Autonomous Pharmacy through automation and advanced services across its cloud-based platform. The company is on track to meet its 2025 financial goals, supported by increasing tech services and long-term customer partnerships. Its strategic expansion into new regions is also encouraging. However, headwinds from competitive pressures and macroeconomic challenges could adversely affect the company's performance. In the past year, thi ...

Investors might want to bet on Omnicell (OMCL) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook. The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this Omnicell Inc. Should get reflected in its stock price. After all, empirical research shows a strong correlation between trend ...

Omnicell, Inc. (OMCL) recently announced Central Med Automation Service, a subscription-based solution. It is designed to help health systems establish and continuously optimize centralized medication management for Consolidated Pharmacy Services Centers ("CPSCs") and similar operations. About Central Med Automation Service Intended to streamline medication dispensing from a central fulfillment area throughout the entire health system enterprise, this solution is expected to improve inventory visibility, sc ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMNIC ...

Financial Data and Key Metrics Changes - Total revenue for Q2 2024 was $277 million, a sequential increase of $31 million or 12% over the prior quarter, but a decrease of $22 million or 7% compared to Q2 2023 [7][18] - GAAP earnings per share for Q2 2024 were $0.08, compared to a loss of $0.34 in the prior quarter and a profit of $0.08 in Q2 2023 [7][20] - Non-GAAP earnings per share for Q2 2024 were $0.51, compared to $0.03 in the prior quarter and $0.57 in the same period last year [21] - Non-GAAP EBITDA for Q2 2024 was $40 million, an increase of $29 million compared to the previous quarter, but a decrease of $7 million compared to the same period last year [21] Business Line Data and Key Metrics Changes - Product revenues were $157 million, an increase of 17% over the previous quarter but down 17% compared to Q2 2023 [19] - Services revenues were $120 million, an increase of 7% over the previous quarter and an increase of 9% compared to Q2 2023 [19] - Advanced Services represented 22% of total revenue for the first and second quarters of 2024, up from 18% in Q2 2023 [10] Market Data and Key Metrics Changes - The macroeconomic landscape is showing early signs of improvement, with demand for medication management solutions tracking in line with expectations [6][18] - The company anticipates total recurring revenue, including Consumables and Technical Services, to represent approximately 50% of total revenue for the full year 2024 [10][52] Company Strategy and Development Direction - The company is focusing on innovations around its XT platform and offering services expected to increase recurring revenue [5][6] - The XT Amplify program aims to maximize value for healthcare facilities and drive enhanced clinical and operational outcomes [8][9] - The company is committed to prudent expense management while rolling out its innovation agenda [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver consistent performance and improve financial results [5][6] - The demand environment is expected to remain strong, particularly for Specialty Pharmacy Services and point-of-care products [18][28] - Management noted that health systems are expanding, indicating a healthy financial position for customers [71] Other Important Information - The company is updating its full-year 2024 guidance based on strong first-half performance and current visibility [23] - For full-year 2024, total revenues are expected to be in the range of $1.070 billion to $1.110 billion [23] Q&A Session Summary Question: What drove the beat in product revenue for Q2 and what contributed to the guidance revision? - The beat was driven by strong demand in the point-of-care product portfolio and Specialty Pharmacy Services, while the guidance revision reflects implementation schedules and visibility into the second half [28][29] Question: Can you size the cost-saving opportunities identified in the holistic review? - The company expects continued improvement in performance and cost savings through prudent expense management [30] Question: How is the demand environment for compounding and Central Pharmacy Robotics Solutions? - There is significant interest, but deployment is slower as features are adjusted to meet new regulations [32] Question: Can you provide more color on the XT Amplify program and its impact on guidance? - XT Amplify is expected to build backlog but will not significantly contribute to revenues this year; most bookings will hit next year [35] Question: What is the current pricing environment for product revenues? - There have been no major changes in pricing, and the company remains disciplined in its approach [62] Question: How do improving labor trends impact the revenue outlook? - Improved labor availability allows for more efficient installations and customer confidence in implementing systems [59]

Omnicell, Inc. (OMCL) reported second-quarter 2024 adjusted earnings per share (EPS) of 51 cents, which declined 10.5% year over year. However, the metric beat the Zacks Consensus Estimate of 16 cents by a stupendous 218%. Adjustments include one-time expenses like share-based compensations, the amortization of acquired intangibles, acquisition-related expenses, RDS restructuring and others. GAAP EPS was 8 cents, flat year over year. Revenues in Detail Revenues totaled $276.8 million, down 7.4% year over ye ...

Omnicell (OMCL) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.57 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 218.75%. A quarter ago, it was expected that this Omnicell Inc. Would post a loss of $0.08 per share when it actually produced earnings of $0.03, delivering a surprise of 137.50%. Over the last four quarters, the company ...